Abstract:Objective:To explore the expression and clinical significance of EphA2 and Ecadherin in pancreatic cancer tissue and cells.Methods:The expression of EphA2 and Ecadherin in 56 pancreatic carcinomas and 23 adjacent noncancer tissues were studied by immunohistochemistry, and their relationship to clinicopathological characteristics were analyzed. RTPCR was performed to explore the expression of EphA2,BXPC3,PC3 and PANC1 in pancreatic carcinoma cell lines. Results:In pancreatic carcinomas tissuse showed increased EphA2 expression and reduced Ecad expression which compared with adjacent noncancer tissues. The expression level of EphA2 had a significant positive relationship with tumor differentiation degree, lymphatic metastasis and clinical stage. However, the expression level of Ecadherin had negative relationship with both the tumor clinical stage and lymphatic invasion. Furthermore, a significant negative relationship between the expression of EphA2 and Ecadherin was observed. The expressions of EphA2 were higher in highinvasive cell lines PXPC3 and Panc1 than in lowinvasive cell line PC3. Conclusions:The expression and/or abnormal function of EphA2 and Ecadherin may together be involved in the development and progression of pancreatic cancer;the combined measurement of these two proteins may be useful for determination of metastatic potency of pancreatic carcinoma.